X-XSS-Protection: 1; mode=block X-Content-Type-Options: nosniff Strict-Transport-Security: max-age=63072000; includeSubDomains; preload


See. Treat. Cure.

Highly Specific Cancer Targeting

Using its proprietary platform technology, EM Imaging is developing a pipeline of highly novel in vivo c-Met targeting theragnostic and optical imaging agents that will alter the landscape of precision medicine.


EM Imaging has a portfolio of agents addressing a number of unmet medical needs


Ongoing Clinical Studies

EM Imaging is focused on the development of fluorescent optical imaging and therapeutic agents. Our current clinical trials are detailled in a dedicated section. 

Latest Press Release

Our Latest News

Results published by Investigator on Image-guided Surgery in Penile Squamous Cell Carcinoma Patients

This pilot study suggest that c-MET is a promising target for fluorescence-guided tumour identification, with the potential to improve margin assessment in pSCC. The c-MET targeted approach proved to be compatible with lymphatic mapping performed in the same patient using multicolor fluorescence guidance based on both infrared (Cy5) and near-infrared (ICG) imaging.

read more